Research programme: catalytic antibody therapeutics - Ozgene

Drug Profile

Research programme: catalytic antibody therapeutics - Ozgene

Alternative Names: CATAB I - Ozgene; CATAB II - Ozgene; CATAB III - Ozgene; CATAB IV - Ozgene; CATAB V - Ozgene

Latest Information Update: 15 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ozgene
  • Class Catalytic antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Research Alzheimer's disease; HIV infections; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2011 Early research is ongoing in Australia
  • 15 Mar 2011 Research programme: catalytic antibody therapeutics - Ozgene is available for licensing as of 15 Mar 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top